AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 181 min read$ACON

Gould Gregory A purchased $24K of ACON

Gould Gregory A (CFO) purchased 10,000 shares of Aclarion, Inc. (ACON) at $2.45 on 2026-08-14.

Original reporting
SEC EDGAR · Gould Gregory A
Published Aug 18, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market purchase of 10,000 shares at $2.45/share, with post-transaction holdings of 60,000 shares.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no new operational or financial catalyst in the text.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article provides no context on prior holdings, compensation, or whether the buy was opportunistic versus planned.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for Aclarion, Inc. (ACON).

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Aclarion CFO Gould Gregory purchased 10,000 shares of ACON at $2.45/share, totaling $24,500, disclosed via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

Form 4 shows a direct insider purchase, but the transaction size ($24.5k) is modest and there is no accompanying guidance, deal, or operational update in the filing.

Market effects

Sector

No sector-level implications; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine (tax planning, diversification, or compensation-related liquidity) and do not necessarily signal improved fundamentals.

Key entities

  • issuer
    Aclarion, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Gould Gregory

    CFO who reported the open-market purchase.

  • security
    ACON

    Aclarion common stock ticker referenced in the filing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACON insider trading history →

Related articles

OCT 8
$ACONMedAI 8/10

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

rttnews.com2 min
JUN 10
$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

orthospinenews.com4 min
JUN 3
$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.

manilatimes.net4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min